Table 1.
Patient characteristics.
| N = 638 | |
|---|---|
| Characteristic | N (%) |
| ECOG PS | |
| 0 | 464 (72.8) |
| 1 | 153 (23.9) |
| 2 | 21 (3.3) |
| NA | – |
| Line of ET + CDK4/6i treatment | |
| 1 | 335 (52.5) |
| 2 | 158 (24.8) |
| ⩾3 | 145 (22.7) |
| NA | – |
| Type of CDK4/6i | |
| Palbociclib | 529 (82.9) |
| Ribociclib | 74 (11.6) |
| Abemaciclib | 35 (5.5) |
| NA | – |
| CDK4/6i dose reduction | |
| Yes | 266 (41.7) |
| No | 372 (58.3) |
| NA | – |
| Type of ET | |
| AI | 259 (40.6) |
| Fulvestrant | 379 (59.4) |
| NA | – |
| Postmenopausal status | |
| Yes | 530 (83.1) |
| No | 108 (16.9) |
| NA | |
| No. metastatic sites | |
| 1–2 | 458 (71.8) |
| >2 | 180 (28.2) |
| NA | – |
| Visceral disease | 334 (52.4) |
| NA | 1 |
| Bone metastases | 444 (69.6) |
| NA | |
| Liver metastases | 188 (29.5) |
| NA | 1 |
| Lung metastases | 200 (31.3) |
| NA | – |
| Brain metastases | 18 (2.8) |
| NA | – |
| Skin/soft tissue metastases | 86 (13.5) |
| NA | – |
| LN metastases | 303 (47.5) |
| NA | – |
| Age | |
| Median (IQR) | 61 (52–70) |
| NA | – |
| DFI (years) | |
| Median (IQR) | 4.8 (0.8–10.4) |
| NA | 24 |
| ERα in primary tumor | |
| Median (IQR) | 90 (80–95) |
| NA | 47 |
| Progesterone receptor in primary tumor | |
| Median (IQR) | 47.6 (5–85) |
| NA | 54 |
| Ki-67 in primary tumor | |
| Median (IQR) | 24 (13;31) |
| NA | 168 |
Data are presented as absolute numbers (N) and their percentage within the indicated category (%), unless otherwise specified.
AI, aromatase inhibitor; CDK4/6i, Cyclin-Dependent Kinase 4/6 inhibitor; DFI, disease free interval; ECOG PS, eastern cooperative oncology group performance status; ER: estrogen receptor; ET, endocrine therapy; IQR, inter-quartile range; LHRH, luteinizing hormone-releasing hormone; LN, lymph node; N, number; NA, not available.